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Abstract
Background: Many anticancer agents and carcinogens are DNA damaging chemicals and exposure
to such chemicals results in the deregulation of cell cycle progression. The molecular mechanisms
of DNA damage-induced cell cycle alteration are not well understood. We have studied the effects
of etoposide (an anticancer agent), cryptolepine (CLP, a cytotoxic alkaloid), benzo [a]pyrene (BaP,
a carcinogenic polycyclic aromatic hydrocarbon) and 2-amino-1-methyl-6-phenylimidazo [4,5-
b]pyridine (PhIP, a cooked-meat derived carcinogen) on the expression of cell cycle regulatory
genes to understand the molecular mechanisms of the cell cycle disturbance.
Results: A549 cells were treated with DMSO or chemicals for up to 72 h and periodically sampled
for cell cycle analysis, mRNA and protein expression. DMSO treated cells showed a dominant G1
peak in cell cycle at all times examined. Etoposide and CLP both induced G2/M phase arrest yet
the former altered the expression of genes functioning at multiple phases, whilst the latter was
more effective in inhibiting the expression of genes in G2-M transition. Both etoposide and CLP
induced an accumulation of p53 protein and upregulation of p53 transcriptional target genes.
Neither BaP nor PhIP had substantial phase-specific cell cycle effect, however, they induced
distinctive changes in gene expression. BaP upregulated the expression of CYP1B1 at 6–24 h and
downregulated many cell cycle regulatory genes at 48–72 h. By contrast, PhIP increased the
expression of many cell cycle regulatory genes. Changes in the expression of key mRNAs were
confirmed at protein level.
Conclusion: Our experiments show that DNA damaging agents with different mechanisms of
action induced distinctive changes in the expression pattern of a panel of cell cycle regulatory genes.
We suggest that examining the genomic response to chemical exposure provides an exceptional
opportunity to understand the molecular mechanism involved in cellular response to toxicants.
Background
Many chemical carcinogens and therapeutic agents inter-
act with cells, leading to temporary/permanent cell
growth arrest, genetic modification or cell death. The ulti-
mate effect of a chemical on cells is largely determined by
the chemical's ability to elicit genomic response. The
recent launch of the National Institutes of Health NCI
Chemical Genomics Initiative [1] heralds a new era of
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chemical-genome research. In the current study, we have
used chemical-genomics and phenotypic expression to
understand the molecular mechanisms involved in cellu-
lar response to chemical exposure.
We have examined four chemicals. Etoposide, a topoi-
somerase II inhibitor, induces DNA double strand breaks
by promoting the formation of cleavable DNA-protein
complexes and causes cell cycle arrest at S phase or G2/M
phase dependent on the cell type [2,3]. Cryptolepine
(CLP), an alkaloid extracted from the West African climb-
ing shrub Cryptolepis sanguinolenta, interferes with topoi-
somerase II and inhibits DNA synthesis and is potently
cytotoxic to tumor cells [4-6]. Benzo(a)pyrene (BaP), one
of the polycyclic aromatic hydrocarbons (PAHs) derived
from incomplete combustion of organic matter, is an
archetypal procarcinogen. Epidemiological studies indi-
cate a positive link between exposure to BaP and the
occurrence of human cancers [7-9]. BaP exerts its genoto-
xicity  via  cytochrome P450-mediated metabolism,
namely CYP1A1 and CYP1B1, to form electrophiles that
covalently bind to DNA [10,11]. The expression of
CYP1A1 and CYP1B1 can be induced by the activation of
aryl hydrocarbon receptor (AhR), which is a ligand-acti-
vated transcription factor [12]. Upon binding to its lig-
ands, such as dioxin and PAHs, AhR translocates to the
nucleuswhere it complexes with ARNT to stimulate the
transcription of genes via transactivation through
enhancer domains known as AHR-, dioxin-, or xenobi-
otic-response elements [13,14]. The cytochrome P450
Cyp1 family, including CYP1B1 and CYP1A1, as well as
several phase II detoxification genes are among those reg-
ulated by AhR [15,16]. Studies also provide evidence that
AHR participates in the modulation of the transcriptional
program at least in part by associating with additional
transcription factors [17,18]. Such associations may be
responsible for the effects of the ligand-activated AHR in
the regulation of proliferation [19]. 2-Amino-1-methyl-6-
phenylimidazo [4,5-b]pyridine (PhIP), a diet-derived het-
erocyclic amine formed during the cooking of meat [20],
is a rodent carcinogen and suspected human carcinogen.
It is known that PhIP and other heterocyclic amines are
metabolized chiefly by CYP1A2 but also CYP1A1 and
CYP1B1 to form electrophiles that bind to DNA to form
DNA adducts [21-23].
In the current study we have used A549 human lung ade-
nocarcinoma cells to examine the cellular and genomic
responses to the chosen DNA reactive chemicals. The alve-
olar epithelial type II cell-derived A549 cells have been
extensively used to test the cytotoxicity of therapeutic
agents and environment toxicants [24]. These cells express
aryl hydrocarbon receptor (AhR) [25], providing a useful
model for studying AhR mediated gene regulation. Cell
cycle analysis combined with cDNA Microarray assay
allowed us to distinguish the molecular mechanisms of
the cell cycle disturbance induced by the different chemi-
cals and to more precisely predict the fate of cells after
chemical exposure.
Results
Effects of treatments on cell cycle
Cell growth status was examined by microscopy and flow
cytometry. Cells treated with DMSO, BaP and PhIP, but
not etoposide and CLP, reached confluence after 24 h, as
examined under microscope (data not shown). Figure 1
shows that in all DMSO treated samples, a predominant
number of cells distributed in G1 phase of the cell cycle.
In comparison, treatment with etoposide induced a time
dependent decrease in the number of cells in G1 phase
and an accumulation of cells in G2/M phase of the cell
cycle. Cells treated with CLP displayed a cell cycle profile
with elevated G2/M phase peak after 24 h. In comparison,
BaP and PhIP had no persistent cell cycle specific effects.
At 72 h, the sample treated with etoposide exhibited a
nearly 2–3 fold increase in subG1 phase cells, compared
with samples treated differently. Consistent with the
occurrence of subG1 cells, we also observed more floating
cells in the etoposide treated sample compared to the
other treatments at 72 h, suggesting that etoposide
induced cytoxicity at this late timepoint.
Changes in the expression of P53 and its target genes in 
response to chemical treatments
p53 is well-established as a primary responder to cellular
and genetic stress [26]. Many of the p53 transcriptional
target genes are involved in the cell cycle checkpoints. We
have examined the levels of p53 protein together with
some of its transcriptional target genes in response to dif-
ferent chemical treatments (table 1, group 1). Figure 2
shows a low level of p53 protein in DMSO treated cells.
The expression levels of WAF1 and TGF-β mRNA, the pro-
tein products of which are involved in the G1/S transition
cell cycle checkpoint [27,28], increased with time in
DMSO treated cells (Fig. 3A). This pattern of change in the
expression of WAF1 and TGF-β indicates that prolonged
culture caused cell cycle arrest at G1 phase, which was sup-
ported by the observations that the number of cells in G1
phase was increased after 24 h compared with that at 6 h
(Fig, 1). Indeed, after 24 h, cells treated with DMSO
formed a uniform confluent monolayer. Exposure to
etoposide and CLP induced an accumulation of p53 at 6
h and 24 h (Fig. 2). Consistent with this, WAF1, TGF-β,
BAX, MDM2 all showed a positive response to both agents
within 24 h at mRNA level (Fig. 3A, 3B). Although the
ability for etoposide to induce the accumulation of p53
was largely diminished after 48 h (Fig. 2), exposure to the
chemical was still effective in up-regulating WAF1  and
MDM2 (Fig. 3A, 3B) Western blotting analysis also con-
firmed that exposure to etoposide and CLP upregulatedCancer Cell International 2005, 5:28 http://www.cancerci.com/content/5/1/28
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the expression of proteins WAF1, MDM2 family members
and BAX as early as 6 h (Fig. 2). Exposure to BaP and PhIP,
on the other hand, increased the expression of BAX at 24
h (Figs. 2, 3A), but had little effects on any of the other
p53 gene targets during the 72 h of treatment compared
with the DMSO control (Figs. 2, 3A, 3B), consistent with
the inability of these two chemicals to induce the accumu-
lation of p53 protein (Fig. 2). These results suggest that
exposure to both etoposide and CLP induced p53 activa-
tion, whilst etoposide, BaP and PhIP may also activate
p53-independent pathways to regulate the expression of
the so-called p53 target genes in A549 cells.
Effects on genes involved in G1/S transition
Apart from the p53 target genes WAF1 and TGF-β, we have
also examined the expression of other genes involved in
the G1-S phase transition (genes in group 2 in table 1).
These genes showed no appreciable response to the treat-
ments (data not shown) with the exception of CYCLIN
D1, which appeared to be upregulated by exposure to
Effects of chemical treatment on cell cycle Figure 1
Effects of chemical treatment on cell cycle. A549 cells were treated with DMSO (< 0.1% v/v), etoposide (10 µM), BaP (25 µM), 
CLP (2.5 µM) or PhIP (50 µM) for the times indicated. Cell cycle distribution was assessed by flow cytometry. The gating rep-
resents % cells in each phase of the cell cycle. M1: sub-G1; M2:G0/G1 phase; M3: S phase; M4: G2/M phase.
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etoposide, CLP and BaP (Fig. 3C). The effects of all chem-
ical treatments on the expression of G1/S transition genes
seemed to be insufficient to cause cell cycle arrest in G1
phase.
Effects on genes involved in G2/M transition
In DMSO treated cells, the expression levels of genes
involved in G2/M phase transition (Table 1, group 3)
were lowest at 72 h (Fig. 4A), suggesting a low growth
potential in these cells at this stage. Etoposide persistently
inhibited the expression of all these genes. The effects on
CYCLIN A (CCNA2) and  CYCLIN B1 (CCNB1) were
observed as early as 6 h. CLP inhibited the expression of
many of these genes within 24 h and all of them by 72 h.
Interestingly, exposure to BaP also inhibited the expres-
sion of the majority of these genes, although the effects
were not observed before 48 h. Exposure to PhIP, on the
other hand, upregulated some of these genes at the later
timepoints, though the effects were not substantial. These
results suggest that etoposide is the most effective agent in
inhibiting cell cycle progression through G2/M phase
transition. The marginal effect elicited by PhIP indicated a
small growth stimulus competing against confluence-
related growth inhibition.
Effects on genes involved in mitosis
The expression of genes involved in mitosis (Table 1,
group 4) in cells treated with DMSO was lowest at 72 h,
suggesting that the rate of cell division was lowest at this
time point (Fig. 4B). Exposure to etoposide repressed the
expression of all these genes within 6 h of treatment. In
comparison, CLP showed no such inhibition up to 24 h of
treatment, although inhibition was evident at 72 h. Expo-
sure to BaP, again, had no effects on the expression of
these genes before 24 h, but inhibited the expression of all
these genes after 48 h of treatment. In complete contrast,
cells treated with PhIP expressed higher levels of these
mitosis-related genes at the 72 h time point. This suggests
that PhIP either had the potential to delay the growth
inhibition initiated by confluence or exerted a mild
growth stimulation effect.
Effects on genes involved in DNA replication initiation
In cells treated with DMSO, the expression of genes
involved in DNA replication initiation (Table 1, group 5)
Table 1: Genes and their accession number in Genbank
Genes Access. No Genes Access. No
Group 1 Group 4
Waf U03106 CDC25C M34065
TGF-beta AB000584 CENPf U30872
Bax-delt U19599 NEK2 Z2906
Bax-alpha L22473 BUB1 AF053305
MDM2-D U33202 BUB1B AF053306
MMD2-A U33199 TTK M86699
MDM2-E U33203
Group 2 Group 5
Cyclin D1 M64349 CDC34 L22005
CDK4 U37022 CDC45L AJ223728
Cyclin E M74093 MCM2 D21063
E2F M96577 MCM6 D84557
DP1 L23959 MCM7 D55716
Rb M15400 MCM8 D55083
Group 3 Group 6
BIRC3 U75285 CYP11A M14565
CCNB1 M25753 CYP1A1 X02612
CCNA2 X51688 CYP1B1 U03688
CDKN3 L25876 CYP24 L13286
HSCDC6 U77949 CYP2A7 M33317
MYT1 U56816 CYP2B6 M29874
CYP4B1 J02871
CYP51 U23942
Group 1: P53 target genes; group 2: genes involved in G1/S transition; group 3: genes involved in G2/M phase transition; group 4: genes involved in 
mitosis; group 5: genes involved in DNA replication initiation; group 6: CYP genes.Cancer Cell International 2005, 5:28 http://www.cancerci.com/content/5/1/28
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was highest at 6 h (Fig. 5A). Although the expression of
most of these genes had dramatically decreased at 24 h,
there was no time-dependent further decrease thereafter.
This pattern of change suggests that the process of DNA
synthesis initiation was still active when cell growth had
reached confluence. Exposure to etoposide, CLP and BaP
all caused inhibitory effects on the expression of many of
these genes, although the effects of BaP were only appar-
ent after 48 h. Again, in contrast to the other treatments,
PhIP appeared to upregulate the expression of many genes
in this group at the 48 h and 72 h time points. These
results suggest that cells treated with PhIP were more
active in initiating DNA synthesis than cells treated with
DMSO and with the other three agents, again supporting
a growth stimulating effect.
Western blotting was also used to examine the expression
level of a number of gene products (Fig. 2). Consistent
with the data seen at the mRNA level, the protein levels of
cyclin A and cyclin B were much lower at 72 h than any
other time point in DMSO treated cells (Fig. 2). Exposure
to etoposide and CLP decreased the levels of cyclin A and
cyclin B, consistent with their effects on the mRNA levels
of these proteins. Exposure to BaP, which reduced the
mRNA levels of cyclin A and cyclin B at late time points,
also reduced the levels of these proteins. Finally and again
in contrast to the other treatments, at 72 h PhIP treatment
induced the expression of cyclin A, cyclin B and MCM7
proteins (Fig. 2) consistent with a growth stimulatory
effect. These results clearly show that changes at mRNA
level resulted in changes at protein level. The temporal
aspect of altered expression of mRNA to altered expres-
sion of protein depends upon the stability of the respec-
tive message and protein.
Effect on CYP1B1
The expression level of CYP1B1 in DMSO treated cells was
relatively low at 6 h and 24 h but was about 10-fold higher
after 48 h (Fig. 5B). Compared with DMSO, exposure to
BaP induced a time-dependent upregulation of CYP1B1
from 6 h to 24 h (Fig. 5B). The induction of CYP1B1
protein in A549 cells treated with BaP for 24 h was con-
firmed by Western blot (Fig. 5C). The ability of BaP to
increase the expression of CYP1B1 is consistent with the
general perception that this chemical can bind to the AhR,
which is the transcriptional factor of CYP1B1. We have
confirmed the presence of the AhR protein in this cell line
although its expression does not appear to have been
affected by the drug treatments (data not shown). We also
examined the expression of other CYP genes (group 6 in
table 1) and found no appreciable response to the treat-
ments at any of the time points (data not shown).
Discussion
To gain insights into the mechanisms through which
chemicals interfere with cell cycle progression, we moni-
Western blots of p53, p53-transcriptional target gene proteins and proteins involved in cell cycle execution Figure 2
Western blots of p53, p53-transcriptional target gene proteins and proteins involved in cell cycle execution. Lysates from A549 
cells treated as described in Fig. 1. were subjected to SDS-PAGE, electroblotted onto nitrocellulose and probed for specific 
immunoreactive proteins.
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Effects of chemical treatment on mRNA levels of p53 target genes and cyclin D1 in A549 cells that were treated as described  in Fig. 1 were measured using cDNA microarray hybridisation Figure 3
Effects of chemical treatment on mRNA levels of p53 target genes and cyclin D1 in A549 cells that were treated as described 
in Fig. 1 were measured using cDNA microarray hybridisation. A. p53 transcriptional targets (I). B. p53 transcriptional targets 
(II). C. Cyclin D1. GenBank accession number for each gene is displayed in table 1.
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Effects of chemical treatment on mRNA levels of genes involved in G2/M transition and mitosis Figure 4
Effects of chemical treatment on mRNA levels of genes involved in G2/M transition and mitosis. mRNA levels in A549 cells that 
were treated as described in Fig. 1 were measured using cDNA microarray hybridisation. A. G2/M genes. B. Mitosis genes. 
GenBank accession number for each gene is displayed in table 1.
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Effects of chemical treatment on expression of genes involved in DNA replication initiation and CYP1B1 Figure 5
Effects of chemical treatment on expression of genes involved in DNA replication initiation and CYP1B1. mRNA levels in A549 
cells that were treated as described in Fig. 1 were measured using cDNA microarray hybridization and protein levels by West-
ern blotting. A. mRNA levels of DNA replication initiation genes. B. mRNA levels of CYP1B1 C. Expression of CYP1B1 pro-
tein. GenBank accession number for each gene is displayed in table 1.
6h
CDC34
CDC45L
MCM2
MCM6
MCM7
MCM8 0
2500
5000
7500
10000
DMSO
ETOP
BaP
CLP
PhIP
24 h
CDC34
CDC45L
MCM2
MCM6
MCM7
MCM8 0
2500
5000
7500
10000
CDC34
CDC45L
MCM2
MCM6
MCM7
MCM8 0
2500
5000
7500
10000
48 h
72 h
CDC34
CDC45L
MCM2
MCM6
MCM7
MCM8 0
2500
5000
7500
10000
CYP1B1
6h
24 h
48 h
72 h
0
1000
2000
3000
4000
5000
DMSO
VP16
BaP
CLP
PhIP
Time
A
B
C
0 52 55 0 100
BaP (µ µ µ µM)
CYP1B1
H
y
b
r
i
d
i
s
a
t
i
o
n
(
A
r
b
i
t
r
a
r
y
U
n
i
t
s
)Cancer Cell International 2005, 5:28 http://www.cancerci.com/content/5/1/28
Page 9 of 13
(page number not for citation purposes)
tored cell cycle changes by flow cytometry analysis com-
bined with cDNA microarray assay using cells from the
same experiments. Cells treated with DMSO for 6 h
showed well-defined G1 and G2/M phase peaks and a
good proportion of cells distributed in S phase, indicative
of proliferation status. The G2/M phase peak was smaller
at 24 h and not readily discernable at 48 h and 72 h, indi-
cating that cell growth had reached stationary phase at this
late stage of the culture. An increase of cytoxicity was
detected in cells treated with etoposide for 72 h. We exam-
ined the nature of etoposide-induced cytotoxicity and
found no degradation of PARP and caspase-3, well docu-
mented features of apoptotic cell death (data not shown).
Although exposure to etoposide appeared to induce cell
cycle arrest predominantly at G2/M phase, global gene
expression analysis suggested that at the dose used (10
µM) the chemical has the ability to inhibit cell cycle pro-
gression at multiple stages. It effectively caused an accu-
mulation of p53 protein, which leads to the up-regulation
of its transcriptional gene targets. Included in these gene
targets were Waf1 and TGF-β, both protein products are
involved in the G1 checkpoints with WAF1 also being
involved in G2/M checkpoint. Additionally, etoposide
inhibited the expression of many other genes that func-
tion in the execution of cell cycle progression through S
phase, G2/M transition and mitosis.
Although exposure to CLP induced a cell cycle profile sim-
ilar to that induced by etoposide at the 24 h, there was a
preferential inhibition of the expression of genes involved
in G2/M transition. This contrasts with etoposide, which
was more effective in inhibiting the expression of genes
controlling both G2/M phase and mitosis.
BaP and PhIP treated cells showed no obvious phase spe-
cific effect on cell cycle progression over the period of
study (72 h). The lack of effect of polycyclic aromatic
hydrocarbon carcinogens on cell cycle in cells, including
A549 cells, has been reported by others and described as
stealth carcinogenesis [29]. Exposure to BaP and PhIP had
little, if any, effect on the expression of cell cycle regula-
tory genes at the 6 h and 24 h time points. However, after
prolonged treatment (48 – 72 h), BaP and PhIP induced
alterations in the expression of many cell cycle regulatory
genes. The effects exerted by BaP and PhIP on gene expres-
sion were not associated with dramatic changes in cell
cycle profile, which may be due to a delay in the ability of
the chemicals to influence transcription by which time the
cells had achieved confluence.
p53 protein accumulation often occurs as an indicator of
DNA damage [30,31]. The products of p53 transcriptional
target genes are known to play important roles in multiple
cellular biological processes, including cell cycle check-
point control [32,33], DNA synthesis [34], DNA damage
repair [26] and apoptosis [35]. P53 selectively regulates
the expression of its targets in response to certain treat-
ments [36]. Moreover, it has been found that some p53
target genes are also regulated in a p53-independent man-
ner [37,38]. Our experiments in A549 cells showed that
etoposide and CLP were almost equally effective in induc-
ing the accumulation of p53 protein at 6 h of treatment,
whilst BaP and PhIP failed to do so up to 72 h. We selected
a number of p53 target genes to determine whether the
dynamics of their expression was altered by the various
chemical treatments applied. It was observed that both
etoposide and CLP showed similar patterns of effects on
the expression of some p53 target genes, including Waf1,
MDM2 and TGF-β and Bax, although the etoposide effects
were more prominent. The ability of etoposide and CLP to
affect the expression of the p53 target genes was not
reflected in changes in the expression of these protein
products. This was exemplified by the observation that
CLP was more effective than etoposide in upregulating the
expression of MDM2 protein despite being less effective in
upregulating the expression of MDM2  at mRNA level.
These results suggest that there must be differences in the
post-transcriptional regulation of the expression of
MDM2 protein in response to the treatments of etoposide
and CLP.
MDM2 acts as an E3 ubiquitin ligase which mediates aut-
oubiquitination and ubiquitination of other proteins
including p53 [39]. The balance between auto- and sub-
strate-ubiquitination of MDM2 is modulated physiologi-
cally by posttranslational modifications, including
sumoylation and phosphorylation. If SUMO conjugates
to MDM2, its E3 ligase activity is shifted toward p53,
while self-ubiquitination is minimized [40]. The tumour
suppressor P19ARF associates with MDM2 to inhibit the
ubiquitination, export and subsequent degradation of
p53 [41,42]. Given that MDM2 sumoylation is also stim-
ulated significantly by ARF [43], SUMO and ubiquitin
modifications appear to be mutually antagonistic. The
switch in modification status is stress-responsive, because
UV irradiation leads to loss of MDM2 sumoylation [44].
Further study will be needed to investigate whether CLP
and etoposide induce different modification of MDM2.
More interestingly, it was observed that p53 protein was
much reduced in cells treated with etoposide for 48 h and
72 h, compared with those treated with CLP at the same
time points. This suggests that etoposide and CLP influ-
ence the expression of p53 by different mechanisms. The
fact that etoposide remained effective in altering the
expression of the so-called p53 target genes in the absence
of p53 protein accumulation suggests that exposure to
etoposide may also result in regulation of genes via p53-
independent mechanisms. BaP and PhIP, neither ofCancer Cell International 2005, 5:28 http://www.cancerci.com/content/5/1/28
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which effected p53 protein, selectively increased the
expression of Bax and its protein product at 24 h but had
little effect on other p53 regulated genes. Again it seems
that exposure to BaP and PhIP can result in regulation of
the expression of BAX via a p53-independent mechanism.
The p53-independent regulation of BAX has been previ-
ously reported [38].
Among the many CYPs, CYP1A1 and CYP1B1 are major
enzymes involved in the metabolism of procarcinogen
PAHs to their DNA reactive species [45,46]. It has been
shown that A549 cells express AhR and both CYP1A1 and
CYP1B1 [25] and are able to activate BaP to form DNA
adducts [[47] and our unpublished data]. In the present
study we found that A549 cells treated with DMSO consti-
tutively express more CYP1B1 mRNA than CYP1A1 mRNA
(data not shown) The expression of CYP1B1  increased
dramatically after treatment with DMSO for 48 h and 72
h compared with those treated for shorter times yet
DMSO is not thought to induce this enzyme. It has been
reported that CYP1B1  is a senescence related gene in
human cells and in mouse cells [48,49], thus the late
increase in the expression of CYP1B1 in DMSO treated
cells may be related to confluence-mediated cell growth
inhibition. BaP drastically increased the expression of
CYP1B1 mRNA at early times with little effect on CYP1A1
mRNA (data not shown), suggesting that in A549 cells
CYP1B1 may be the key enzyme in metabolizing BaP. The
early upregulation of CYP1B1 in response to exposure to
BaP was followed by downregulation of many cell cycle
regulatory genes, supporting the proposal that CYP1B1
protein may have an important role in the regulation of
cell cycle. Alternatively, the downregulation of key genes
for cell cycle progression induced by BaP may be mediated
by the interaction of AhR with other transcription factors.
By 72 h, the expression of key cell cycle regulatory genes
in DMSO treated cells was lowest (measured at mRNA
and protein level), indicating the status of growth inhibi-
tion. However many genes, particularly those involved in
regulating the cell cycle in mitosis phase and in initiating
DNA synthesis, were expressed higher in PhIP treated cells
at this late time point, implying that cells treated with
PhIP retain the potential to proliferate at confluence
phase. At present it is unclear whether the effects of PhIP
on cell cycle progression are due to DNA reactivity or to an
epigenetic mechanism. However, our results are coinci-
dent with the report that PhIP activates the MAP kinase
pathways in MCF-10A cells [50] and MCF7 cells [51]. The
ability of PhIP to enhance cell growth signals under con-
straint culture conditions may be important to its carcino-
genic properties.
Conclusion
Studying mRNA expression in concert with cellular
dynamics provides an effective way of understanding
molecular mechanisms of action of chemicals that interfer
with cell cycle progression. We have shown that exposure
to the DNA intercalating chemicals etoposide and CLP
can rapidly induce cell cycle disturbance by inhibiting the
expression of multiple cell cycle regulatory genes, whereas
the chemical carcinogens BaP and PhIP are insidious and
pronounced cellular change requires more prolonged
treatment. We conclude that the present work has identi-
fied a panel of genes that are responsive to the chosen
chemicals and provides evidence supporting the proposal
that genomic manipulation with chemicals will influence
cellular outcome and that the nature and temporal aspects
of the genomic response is predictive of prognosis.
Materials and methods
All reagents were purchased from Sigma-Aldrich (Poole,
UK) unless otherwise indicated.
Cell culture and treatments
The human lung adenocarcinoma cell line A549 (Euro-
pean Collection of Cell Cultures, Wiltshire, UK) was cul-
tured in Ham's F12 medium supplemented with l-
glutamine (2 mM), 10% fetal bovine serum and 10 µg/ml
gentamicin (all from Invitrogen, Paisley, UK) in a humid-
ified incubator at 37°C with 5% CO2. When 70 % conflu-
ence was reached, cells were treated with DMSO (< 0.1%
v/v), etoposide (10 µM), benzo(a)pyrene (25 µM), cryp-
tolepine (2.5 µM) (gift from Dr Addae-Kyeremeh, Univer-
sity of Science and Technology, Kumasi, Ghana) and PhIP
(50 µM) (purchased from Toronto Research Chemicals,
Canada), for up to 72 h. All cells were harvested using
0.1% trypsin solution in EDTA.
Flow cytometry
Cellular DNA content was determined by propidium
iodide staining flow cytometry as described previously
[52].
Western blotting
Cell lysates (10 µg protein) were resolved by SDS-polyacr-
ylamide gel electrophoresis, electroblotted onto nitrocel-
lulose (0.45 µm), and blocked by incubation in 5%
nonfat dry milk in phosphate buffered saline for 1 h at
room temperature. The nitrocellulose was incubated with
primary antibody overnight at 4°C, followed by second-
ary antibody conjugated to horseradish peroxidase for 1 h
at room temperature. Detection was achieved using ECL
kit (Amersham Life Science, UK). The antibodies against
p53 (sc-6243), Bax (sc-493), cyclin A (sc-751), cyclin B
(sc-752) and MCM7 (sc-9966) were purchased from
Santa cruz, (California, USA). Antibody against p21/waf1
(CP74) was purchased from Neomarkers (Fremont, USA).Cancer Cell International 2005, 5:28 http://www.cancerci.com/content/5/1/28
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Antibody against MDM2 (OP114) was purchased from
CN Biosciences (Nottingham, UK).
DNA Microarray Assay
Total RNAs were prepared with the RNeasy Mini Kit (Qia-
gen), according to manufacture's instruction. Ten µg of
total RNA was reverse transcribed to cDNA by using T7-
(dT)24 primer and Super Script Double-stranded cDNA
Synthesis Kit (Invitrogen). Biotin-labeled cRNA was syn-
thesized from cDNA by using ENZO bioArray High Yield
RNA Transcript Labeling Kit (Enzo Diognostics). The
cRNA samples were hybridized to human GeneChip
arrays containing approximately 12,000 human genes
(Human Genome U95A, Affymetrix). All analyses were
performed at the Affymetrix core facility (Microarray Cen-
tre, Hammersmith Hospital, Imperial College London),
in accordance with the MAIME protocol [53]. The average
intensity of all genes on each chip was adjusted to 1,500
to allow for comparison and subsequent analysis [54].
Gene grouping
All genes were categorized according to the MAPP files
from the GenMAPP database http://www.genmapp.org/
[55]. Due to a failure in sample processing, data at 48 h
was not available for agent CLP.
Real-Time quantitative RT-PCR
Total RNA samples from preparations used for the Gene-
Chip hybridisation were also used as templates for Real-
time quantitive RT-PCR to confirm the microarray expres-
sion data. Reverse transcription was performed using
SuperScriptII (Invitrogen). For each RNA sample, three
cDNAs and one negative control (no transcriptase) were
synthesized by using 2 µg of RNA sample and 0.2 µg/µl
random hexamer primer, in total volume of 20 µl. RT-PCR
was performed using Applied Biosystems 7900 sequencer.
Primers and probes were purchased from Applied Biosys-
tems and designed within an exon for each gene using the
Primer Express program, version 1.5 (sequences are avail-
able on request). Each reaction contained 200 nM forward
and reverse primers, 200 nM probe, 5 µl cDNA template,
12.5 µl Taqman mastermix 2× (Applied Biosystems) and
ddH2O q.f to 25 µl. The cycling parameters were an initial
50°C for 2 mins and 95°C 10 mins, followed by 40 cycles
of 95°C for 15 s and 60°C for 1 min. We used primers and
a probe corresponding to the housekeeper gene 18 s rRNA
to which we normalized the expression of genes of inter-
est. Data was retrieved from SDS2.0 software (Applied
Biosystems) and analysed using the SAS system for Win-
dows: Release 8.01 TS level 01M0.
Validation of the DNA microarray data
We employed real-time PCR to quantify 9 DNA-repair
gene targets (Table 2) and used the data to validate the
DNA microarray assay. Results of the two assays were
compared and the correlation coefficients are presented in
table 2. The two assays showed good consistency with an
overall correlation of > 0.73.
Abbreviations
BaP, benzo(a)pyrene; DMSO, dimethyl sulphoxide; PAH,
polycyclic aromatic hydrocarbon; PhIP, 2-amino-1-
methyl-6-phenylimidazo [4,5-b]pyridine; CLP, Cryp-
tolepine; ETOP, etoposide.
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